Stock Price Quote

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE1400.702.95 (+0.21 %)
PREV CLOSE ( ) 1397.75
OPEN PRICE ( ) 1396.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 74419
TODAY'S LOW / HIGH ( )1382.75 1406.00
52 WK LOW / HIGH ( )1165.55 1672.2
NSE1401.302.6 (+0.19 %)
PREV CLOSE( ) 1398.70
OPEN PRICE ( ) 1394.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1401.30 (35)
VOLUME 1050391
TODAY'S LOW / HIGH( ) 1382.00 1406.10
52 WK LOW / HIGH ( )1165.7 1673
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 17-08 1935
Management Info
Y K Hamied - Chairman Achin Gupta - Managing Director
Registered Office

Address Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower Parel,
Mumbai,
Maharashtra-400013

Phone 022-24826000 / 41916000

Email contactus@cipla.com / cosecretary@cipla.com

Website www.cipla.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg

NEWS

13May Grant Of Stock Options And The Employ
Grant of stock options and employee stock appreciation rights (ESARs)
13May Cipla’s consolidated net profit falls
Cipla has reported results for the fourth quarter (Q4FY26) and year ende..
13May Cipla informs about investor presentat
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
23Apr Cipla’s arm gets USFDA’s final nod for
Cipla’s wholly owned subsidiary -- Cipla USA Inc (Cipla) has received fi..
23Apr Cipla informs about disclosure
Pursuant to the provisions of Regulation 30 read with Schedule III Part..

Financials

in Millions
QTR Mar 26 ANNUAL 26
Net Profit3846.435151.8
Gross Profit 5224.8 46359.4
Operating Profit 7783.355890.4
Net Sales 42099.8189799.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Torrent Pharma (BSE)
peergroup  4418.70 (1.87%)
M.Cap ( in Cr)149548.89
Sanofi Cons. Health (BSE)
peergroup  4770.60 (1.29%)
M.Cap ( in Cr)10986.99
JB Chem & Pharma (BSE)
peergroup  2169.50 (1.78%)
M.Cap ( in Cr)34833.21
Strides Pharma Scien (BSE)
peergroup  1042.95 (1.52%)
M.Cap ( in Cr)9613.15
Jenburkt Pharma (BSE)
peergroup  1137.70 (1.26%)
M.Cap ( in Cr)502.10

Shareholding Pattern

PROMOTERS 29.21%
MUTUAL FUNDS/UTI 18.66%
NON-INSTITUTION 16.26%
FI/BANKS/INSURANCE 11.29%
GOVERNMENT 0%
FII 0%

About Cipla Ltd.

Cipla Ltd. was incorporated in the year 1935. Its today's share price is 1400.7. Its current market capitalisation stands at Rs 113154.89 Cr. In the latest quarter, company has reported Gross Sales of Rs. 200650.4 Cr and Total Income of Rs.201061.5 Cr. The company's management includes Mandar Purushottam Vaidya, Rajendra Chopra, Achin Gupta, Sharmila Paranjpe, Maya Hari, Balram Bhargava, Kamil Hamied, Adil Zainulbhai, Abhijit Joshi, P R Ramesh, Y K Hamied.

It is listed on the BSE with a BSE Code of 500087 , NSE with an NSE Symbol of CIPLA and ISIN of INE059A01026. It's Registered office is at Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower ParelMumbai-400013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are RGN Price & Co, RS Bharucha & Co, V Sankar Aiyar & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.